Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.54 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7897208 | 0.86 | CNR2 (0.51) | HRH3CNR2NAMPT | |
| SCHEMBL600463 | 0.85 | HRH3 (0.53) | CCR2HRH3KCNH2IRAK4 | |
| SCHEMBL599473 | 0.84 | HRH3 (0.59) | HRH3KCNH2 | |
| SCHEMBL600085 | 0.81 | HRH3 (0.61) | HRH3KCNH2 | |
| SCHEMBL601008 | 0.81 | HRH3 (0.56) | HRH3KCNH2IRAK4 | |
| SCHEMBL10123101 | 0.80 | HRH3 (0.54) | HRH3KCNH2IRAK4 | |
| SCHEMBL599236 | 0.80 | HRH3 (0.59) | HRH3KCNH2 | |
| SCHEMBL599096 | 0.79 | HRH3 (0.56) | HRH3KCNH2 | |
| SCHEMBL3861953 | 0.78 | HRH3 (0.57) | HRH3KCNH2IRAK4 | |
| SCHEMBL1507326 | 0.78 | HRH3 (0.74) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391617-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | claimed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | claimed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | claimed |
| EP-2391617-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | disclosed |
| EP-2391617-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | disclosed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | disclosed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | disclosed |
| EP-2391617-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | Evotec AG (DE) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010086403-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | HRH3, HRH2, HRH1 | CCR2 994/4885HRH3 1/4885KCNH2 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.